Otrexup Generic: When Will Generic Methotrexate Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Otrexup Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? May 2031 About 4.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet
- When does the last patent end? May 2031 15 patents listed with the FDA
- Can you buy a generic today? Yes 3 companies list one
It already is. A generic methotrexate is listed for sale by 3 companies, so ask your pharmacy whether it can fill your prescription with one.
Why May 2031?
It is when Otrexup’s patent 8,814,834 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it toss-up: still unsettled. Just as likely to slip as to hold.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Otrexup, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Otrexup by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Toss-up Still unsettled. Just as likely to slip as to hold.
- Price competition
- None filed yet No filers on record
- Brand sales
- $15M a yearSmaller seller
- FDA approved 2013 October 2013 FDA Orange Book
- Patents listed 15 last runs to May 2031 FDA Orange Book
- Pharmacies pay $475.81 per mL NADAC, August 2026
- Medicare Part D spent $4.7M in 2025, for 1,178 people CMS Part D Spending by Drug
- Medicaid prescriptions 763 in the last four reported quarters, $643.7K CMS Medicaid drug utilization, to Q1 2026
Otrexup’s Road to a Generic
Otrexup has had the market to itself since the FDA approved it in October 2013 (Cosette Pharmaceuticals Inc). Its 15 listed patents run to May 2031 (5 already expired).
The first generic of Otrexup is expected in May 2031.
Why that month: patent 8,814,834, on the product’s formulation, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Otrexup Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Otrexup’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 8,814,834, which ends in May 2031, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,562,564 | The product’s formulation | January 2026 | Expired |
| 9,533,102 | The product’s formulation | January 2026 | Expired |
| 9,629,959 | The product’s formulation | January 2026 | Expired |
| 11,446,441 | The product’s formulation | January 2026 | Expired |
| 8,021,335 | The product’s formulation | October 2026 | Expired |
| 9,867,949 | The product’s formulation | March 2029 | Active |
| 10,709,844 | The product’s formulation | March 2029 | Active |
| 11,684,723 | The product’s formulation | March 2029 | Active |
| 8,480,631 | The product’s formulation; a way of using it (U-1442) | March 2030 | Active |
| 8,579,865 | The product’s formulation; a way of using it (U-1442) | March 2030 | Active |
| 8,945,063 | The product’s formulation; a way of using it (U-1442) | March 2030 | Active |
| 9,421,333 | The product’s formulation; a way of using it (U-1442) | March 2030 | Active |
| 11,497,753 | The product’s formulation | March 2030 | Active |
| 12,357,642 | The product’s formulation | March 2030 | Active |
| 8,814,834 Sets the expected month of generic availability | The product’s formulation | May 2031 | Active |
Source: FDA Orange Book, application 204824. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Methotrexate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Otrexup yet.
Approved by the FDA
Not yet. The FDA has not approved a generic methotrexate. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Yes. A generic methotrexate is listed for sale by 3 companies. Ask your pharmacy whether it can fill your prescription with it.
Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited and Eugia US LLC
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Otrexup Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Otrexup 25 mg/0.4 mL auto-inj
$475.81 per mL in August 2026.
Hover over or tap anywhere on the chart to see that month’s price.
- Otrexup 15 mg/0.4 mL auto-inj $484.21 per mL
- Otrexup 20 mg/0.4 mL auto-inj $480.86 per mL
- Otrexup 25 mg/0.4 mL auto-inj $475.81 per mL
See the numbers
| Month | Pharmacies paid per mL |
|---|---|
| August 2026 | $475.81 |
| July 2026 | $475.81 |
| June 2026 | $475.81 |
| May 2026 | $475.81 |
| April 2026 | $475.81 |
| March 2026 | $475.81 |
| February 2026 | $475.81 |
| January 2026 | $475.81 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Otrexup today: $475.81 per mL for Otrexup 25 mg/0.4 mL auto-inj in August 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Dollar figures apply FDA’s median drops to the $475.81 pharmacies pay per mL today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Otrexup
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Otrexup, before manufacturer rebates.
- $17.4K
- January to March 2026, the latest CMS has posted
For 13 people, about $791 per prescription fill - $4.7M
- 2025, the whole year
For 1,178 people, about $956 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $17,396 | 13 | $790.73 |
| 2025 | $4,701,902 | 1,178 | $955.87 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Otrexup only, so no generic is counted in it. What CMS says it is used for: Methotrexate is used to treat severe psoriasis that has not responded to other treatments or rheumatoid arthritis. It may also be used to treat a certain type of arthritis in children (polyarticular juvenile idiopathic arthritis - pJIA).
Medicaid Prescriptions by Quarter
763 prescriptions in the four quarters to Q1 2026, $643.7K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 235 | $199,843 |
| Q2 2025 | 528 | $443,836 |
| Q1 2025 | 520 | $430,554 |
Source: CMS Medicaid State Drug Utilization Data, over Otrexup’s own package codes.
Otrexup Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 10MG/0.4ML (10MG/0.4ML) | Solution | Subcutaneous | October 2013 | Discontinued reference product |
| 15MG/0.4ML (15MG/0.4ML) | Solution | Subcutaneous | October 2013 | Discontinued reference product |
| 20MG/0.4ML (20MG/0.4ML) | Solution | Subcutaneous | October 2013 | Discontinued reference product |
| 25MG/0.4ML (25MG/0.4ML) | Solution | Subcutaneous | October 2013 | Discontinued reference product |
| 7.5MG/0.4ML (7.5MG/0.4ML) | Solution | Subcutaneous | November 2014 | Discontinued reference product |
| 12.5MG/0.4ML (12.5MG/0.4ML) | Solution | Subcutaneous | March 2016 | Discontinued reference product |
| 17.5MG/0.4ML (17.5MG/0.4ML) | Solution | Subcutaneous | March 2016 | Discontinued reference product |
| 22.5MG/0.4ML (22.5MG/0.4ML) | Solution | Subcutaneous | March 2016 | Discontinued reference product |
Source: FDA Orange Book, Cosette Pharmaceuticals Inc. Listed for sale today by Antares Pharma, Inc. (FDA NDC Directory).
Otrexup NDC Codes and Packages
Each Otrexup package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 54436-0010-01 | METHOTREXATE 10 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0010-01 | METHOTREXATE 10 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0010-03 | METHOTREXATE 10 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0010-03 | METHOTREXATE 10 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0010-04 | METHOTREXATE 10 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0010-04 | METHOTREXATE 10 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0012-01 | METHOTREXATE 12.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0012-01 | METHOTREXATE 12.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
Show the other 34 Otrexup packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 54436-0012-03 | METHOTREXATE 12.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0012-03 | METHOTREXATE 12.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0012-04 | METHOTREXATE 12.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0012-04 | METHOTREXATE 12.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0015-01 | METHOTREXATE 15 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0015-01 | METHOTREXATE 15 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0015-03 | METHOTREXATE 15 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0015-03 | METHOTREXATE 15 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0015-04 | METHOTREXATE 15 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0015-04 | METHOTREXATE 15 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0017-01 | METHOTREXATE 17.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0017-01 | METHOTREXATE 17.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0017-03 | METHOTREXATE 17.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0017-03 | METHOTREXATE 17.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0017-04 | METHOTREXATE 17.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0017-04 | METHOTREXATE 17.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0020-01 | METHOTREXATE 20 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0020-01 | METHOTREXATE 20 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0020-03 | METHOTREXATE 20 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0020-03 | METHOTREXATE 20 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0020-04 | METHOTREXATE 20 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0020-04 | METHOTREXATE 20 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0022-01 | METHOTREXATE 22.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0022-01 | METHOTREXATE 22.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0022-03 | METHOTREXATE 22.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0022-03 | METHOTREXATE 22.5 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0022-04 | METHOTREXATE 22.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0022-04 | METHOTREXATE 22.5 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0025-01 | METHOTREXATE 25 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0025-01 | METHOTREXATE 25 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0025-03 | METHOTREXATE 25 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0025-03 | METHOTREXATE 25 mg/.4mL injection, solution | syringe of .4 mL | Antares Pharma, Inc. |
| 54436-0025-04 | METHOTREXATE 25 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
| 54436-0025-04 | METHOTREXATE 25 mg/.4mL injection, solution | carton of 4 syringes of .4 mL | Antares Pharma, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Otrexup’s own FDA approval (NDA 204824) are listed, never a generic. Some codes belong to companies that repackage Otrexup: it is the same medicine in a different package.
What a Generic Otrexup Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Otrexup
Is there a generic for Otrexup right now?
Yes. The FDA NDC Directory lists a generic methotrexate from 3 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Otrexup go generic?
It already has. The FDA NDC Directory lists a generic methotrexate from 3 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic methotrexate be the same as Otrexup?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Otrexup?
Not yet. The FDA Orange Book lists no approved generic version of Otrexup.
When does the Otrexup patent expire?
The FDA Orange Book lists 15 patents for Otrexup; the last runs to May 2031. The one behind the expected month is patent 8,814,834, which ends in May 2031. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (May 2031) weighs all of that.
How much does Otrexup cost now?
Pharmacies paid about $475.81 per mL for Otrexup 25 mg/0.4 mL auto-inj in August 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected May 2031 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- VazaloreAspirinSeptember 2032
- DaurismoGlasdegib MaleateNovember 2032
- IlluccixGallium Ga-68 GozetotideJuly 2035
- NereusTradipitantApril 2039
- RhapsidoRemibrutinibJanuary 2043
- AcuvailKetorolac TromethamineTBD no date yet
About Otrexup
- Generic name methotrexate
- How it is taken Injection under the skin
- Company Cosette Pharmaceuticals Inc
- More drugs Brand-name drugs starting with O
- Have a question? A pharmacist answers, free. Ask about Otrexup
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.